Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492061 | 0.84 | TTR (0.47) | PTPRCTDP1HPGDHTTTSHR | |
| SCHEMBL17929738 | 0.83 | TSHR (0.46) | PTPRCTDP1HPGDTSHRTP53 | |
| SCHEMBL6700180 | 0.82 | MAPT (0.35) | TSHRMAPTCYP1A2ALDH1A1 | |
| SCHEMBL3203499 | 0.82 | ACE2 (0.51) | PTPRCTDP1HPGDHTTTSHR | |
| SCHEMBL29625010 | 0.82 | PTPRC (0.42) | PTPRCTDP1HPGDHTTTSHR | |
| SCHEMBL616934 | 0.81 | ACE2 (0.42) | PTPRCTDP1HPGDHTTTSHR | |
| SCHEMBL8382167 | 0.80 | ACE2 (0.49) | PTPRCTDP1HPGDTSHRTP53 | |
| SCHEMBL5112106 | 0.78 | NOTUM (0.51) | TDP1HPGDHTTTSHRTP53 | |
| SCHEMBL2312050 | 0.77 | HTT (0.41) | PTPRCTDP1HPGDHTTTSHR | |
| SCHEMBL588825 | 0.76 | TTR (0.56) | PTPRCTDP1HPGDHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730892-B2 | Homoallylamines as formaldehyde-responsive triggers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-04 | — | — | US | disclosed |
| US-20180215773-A1 | HOMOALLYLAMINES AS FORMALDEHYDE-RESPONSIVE TRIGGERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-08-02 | — | — | US | disclosed |
| WO-2017034927-A1 | HOMOALLYLAMINES AS FORMALDEHYDE-RESPONSIVE TRIGGERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-02 | — | — | WO | disclosed |
| US-7572790-B2 | Biphenyl carboxylic amide p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572790-B2 | Biphenyl carboxylic amide p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572790-B2 | Biphenyl carboxylic amide p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| EP-1805132-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-06-07 | — | — | US | disclosed |
| WO-2006110173-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1608616-A1 | BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004089874-A1 | BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | POLNIASZEK RICHARD P (US) | 2004-03-25 | — | — | US | disclosed |
| US-6639082-B2 | Cycloboronate intermediates; endothelin antagonists useful, inter alia, for the treatment of hypertension. | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1328523-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | Bristol-Myers Squibb Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | disclosed |
| WO-2002032884-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK7 | PTPRC 1815/4885TDP1 2707/4885HPGD 1788/4885 |
| US-20180215773-A1 | HOMOALLYLAMINES AS FORMALDEHYDE-RESPONSIVE TRIGGERS | HCAR2, HCAR1, HTR2A | PTPRC 2484/4885TDP1 1137/4885HPGD 148/4885 |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | REN, STS, CYP4X1 | PTPRC 3486/4885TDP1 3705/4885HPGD 864/4885 |
| US-10730892-B2 | Homoallylamines as formaldehyde-responsive triggers | HCAR2, MTHFD2, AHCY | PTPRC 2882/4885TDP1 926/4885HPGD 152/4885 |
| US-20080051416-A1 | Novel Compounds | MAPK1, MAPKAPK2, MAPK6 | PTPRC 1772/4885TDP1 2674/4885HPGD 1587/4885 |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | EDNRA, EDNRB, ECE1 | PTPRC 3721/4885TDP1 1946/4885HPGD 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.